192632-34-1

Upstream product

• 192632-33-0 ethyl 3-formaminobenzoate 
• 582-33-2 3-aminobenzoic acid ethyl ester 
• 64-17-5 ethanol 
• 51524-84-6 meta-(methylamino)benzoic acid 
• 344462-84-6 tert-butyl [3-(ethoxycarbonyl)phenyl]carbamate 
• 50-00-0 formaldehyd 

Downstream Products

• 1295605-61-6 C₁₇H₁₈BrN₃O₃ 
• 1330785-56-2 (3-ethoxycarbonylphenylimino)-acetic acid ethyl ester 
• 1217088-67-9 C₁₀H₁₀N₂O 
• 1028293-49-3 (3-{methyl-[4-(2-methyl-imidazo[4,5-c]pyridin-1-ylmethyl)-benzenesulfonyl]-amino}-phenyl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Reductive N-methylation of amines with calcium hydride and Pd/C catalyst

The methylation of amines by paraformaldehyde in the presence of calcium hydride as a source of hydrogen and palladium on charcoal as catalyst was studied. Depending on the quantity of paraformaldehyde, monomethylated and dimethylated amines were selectively and efficiently prepared in one pot with good yields.

Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome

Here we employed structure-based ligand discovery techniques to explore a recently determined crystal structure of the 5-hydroxytryptamine 2B (5-HT2B) receptor. Ten compounds containing a novel chemical scaffold were identified; among them, seven molecules were active in cellular function assays with the most potent one exhibiting an IC50 value of 27.3 nM. We then systematically probed the binding characteristics of this scaffold by designing, synthesizing, and testing a series of structural modifications. The structure-activity relationship studies strongly support our predicted binding model. The binding profiling across a panel of 11 5-HT receptors indicated that these compounds are highly selective for the 5-HT2B receptor. Oral administration of compound 15 (30 mg/kg) produced significant attenuation of visceral hypersensitivity in a rat model of irritable bowel syndrome (IBS). We expect this novel scaffold will serve as the foundation for the development of 5-HT2B antagonists for the treatment of IBS.

SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS

Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

Metal hydride mediated reduction of 3-(alkylthio)oxifidoles containing other potentially reducible groups

The reduction of several 3-(methylthio)oxindoles bearing ester groups on the benzene ring has been studied. The reaction is very dependent on the substitution of the oxindole, and the position of the ester group. Deprotonation of the C3 center by the metal hydride is the major initial pathway. This deprotonation plays a role in the reduction of the pendant ester group. Ester groups ortho, and presumably para, to C3 are very difficult to reduce, reaction only occurring with excess LiAlH4 at elevated temperatures. Once reduction starts, it is very difficult to stop, with reduction of the ester to a methyl group being observed. When deprotonation at this center is blocked, ester reduction becomes straightforward and can be accomplished at room temperature with LiEt3BH.